Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Tetsumasa Yamashita"'
Autor:
Shogo Nakamoto, Tadahiko Shien, Takayuki Iwamoto, Shinichiro Kubo, Mari Yamamoto, Tetsumasa Yamashita, Chihiro Kuwahara, Masahiko Ikeda
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) are the standard agents for treating patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer (ER + HER2 − ABC). However, mar
Externí odkaz:
https://doaj.org/article/095db8af48464a8a8b01067338c59fbf
Autor:
Shogo Nakamoto, Masahiko Ikeda, Shinichiro Kubo, Mari Yamamoto, Tetsumasa Yamashita, Akifumi Notsu
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract Although paclitaxel plus bevacizumab (PB) therapy is an effective chemotherapeutic regimen for HER2-negative advanced breast cancer (ABC), predictive markers for its effectiveness remain undefined. We investigated the usefulness of systemic
Externí odkaz:
https://doaj.org/article/14dd1034bcb343bd9620773f8414331d
Autor:
Toshiaki Akahane, Naoki Kanomata, Oi Harada, Tetsumasa Yamashita, Junichi Kurebayashi, Akihide Tanimoto, Takuya Moriya
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background Next-generation sequencing (NGS) has shown that recurrent/metastatic breast cancer lesions may have additional genetic changes compared with the primary tumor. These additional changes may be related to tumor progression and/or dr
Externí odkaz:
https://doaj.org/article/4a94328c201145c397ad92c2dc7126b0
Autor:
Toshiro Shimo, Katsuhiro Tanaka, Ryohei Ogata, Wataru Saito, Yusuke Ohta, Yoshikazu Koike, Tetsumasa Yamashita, Yutaka Yamamoto, Junichi Kurebayashi
Publikováno v:
Case Reports in Endocrinology, Vol 2014 (2014)
The patient was a 44-year-old woman who exhibited a diffuse goiter during health screening. Her medical history did not include any significant medication-based treatment. An echographic examination detected a solid cystic tumor, which measured 21 ×
Externí odkaz:
https://doaj.org/article/e9c07e9509ec47e1a64c2a8827c65dac
Autor:
Shogo Nakamoto, Masahiko Ikeda, Chihiro Kuwahara, Shinichiro Kubo, Tetsumasa Yamashita, Mari Yamamoto
Publikováno v:
Cancer Diagn Progn
Background/Aim: We investigated the efficacy and safety of sorafenib in Japanese patients and the prognostic value of systemic immunity markers for predicting clinical outcomes after sorafenib therapy in patients with radioiodine refractory different
Publikováno v:
In Vivo
Background: It is unclear whether the de-escalated therapy that omits anthracycline-based chemotherapy is as beneficial as standard therapy for patients with stage I human epidermal growth factor receptor 2-positive (HER2(+)) early breast cancer. Pat
Autor:
Mari Yamamoto, Chihiro Kuwahara, Tetsumasa Yamashita, Shogo Nakamoto, Masahiko Ikeda, Shinichiro Kubo
Publikováno v:
Cancer Diagn Progn
Background/Aim: It has been difficult to establish prognostic markers for overall survival (OS) in patients with advanced breast cancer (ABC). Although systemic immune markers were reported as prognostic markers in several cancers, their utility in A
Publikováno v:
Anticancer research. 41(6)
Background/aim We investigated the usefulness of dynamic changes in absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) during eribulin therapy as predictive markers for survival benefit including post-progression survival (PPS).
Autor:
Mari Yamamoto, Shogo Nakamoto, Masahiko Ikeda, Tetsumasa Yamashita, Shinichiro Kubo, Akifumi Notsu
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Although paclitaxel plus bevacizumab (PB) therapy is an effective chemotherapeutic regimen for HER2-negative advanced breast cancer (ABC), predictive markers for its effectiveness remain undefined. We investigated the usefulness of systemic immunity
Autor:
Takuya Moriya, Toshiaki Akahane, Tetsumasa Yamashita, Oi Harada, Junichi Kurebayashi, Akihide Tanimoto, Naoki Kanomata
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Background Next-generation sequencing (NGS) has shown that recurrent/metastatic breast cancer lesions may have additional genetic changes compared with the primary tumor. These additional changes may be related to tumor progression and/or drug resist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6f56eb7dafca117d1274b500dfc7f56
https://doi.org/10.21203/rs.2.16536/v4
https://doi.org/10.21203/rs.2.16536/v4